well we are all just speculating at this point now.. it might skyrocket on extension or positive PR or it might tank on RS date announcement. I for one sill feel optimistic about this. We'll keep fingers crossed and remember dcth likes Tuesdays.
Who's ready to make money today?
KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
In another 9 hours we go green. GO DCTH!!!. GLTA
A lot of you are on here complaining about this stock like you've invested your entire life's investment into it. If this is the case then you should back away from the stock market and save your money in a savings account. Putting all your eggs in one basket or hoping for some huge profit with a small investment (or your entire life savings) is just so foolish. If you worry about this stock like some of you are posting and are drinking the sorrows or the stock in the red or celebrating a green ending to the trade day is simply stupid and not how the stock market works. And that's my rant today.
so not sure how to post link off my phone. but on stocktwits there is an article going around that in the uk they had used chemosaturation on a woman with breast cancer. and was able to shrink it down to 55% and was able to successfully remove the cancer!.
I bet there are a whole bunch of you waiting to do the Snoopy Dance when this stock goes to a buck.
It just lays there like poop in a pasture ...
This stock is bringing lots of dirt to our comments section lately. I keep muting few of them.
Another good news... it looks like good investors like BNY Mellon and Renaissance Technology have bought in to DCTH.. A confirmation signal if something big happening Check out @UunDaStan message on StockTwits http://stocktwits.com/UunDaStan/message/89568293
UunDaStan shared a chart on StockTwits
$DCTH the other half. Never seen a 420 am Saturday filing. PR Monday morning announcing what we all now know.
Pushing forwards_Merck (MRK) and Delcath Systems (DCTH) to resume negotiations at undisclosed mid town Manhattan conference center on Monday July 24th 2017 projects Sierra. Watch for official news coming soon! Shares of DCTH were trading lower down 5
A blog about buying and selling stocks, penny stocks and online stock trading
This coming week is going to tell the story of a total downfall or to have the knight in shining armor come to rescue the damsel in distress. Sink or swim !!!
till last week I used to think dcth has potential to go near a Dollar but the recent events make me believe this is a serious undervaluation... we are at least looking at $6.
@SAM respect and I agree with you in the pre 14a reverse split but isn't it too late already for DCTH to announce the RS date to avoid delist... doesn't this point to something else up DCTH sleeves?. even an extension is a potential news which would swing stock upwards, we can't be fixated on the 14a ignoring everything else that's been happening around us.
Let me share a scenario with you, what I experienced back in 2008. I took a 50,000 share position in a stock that had plummeted exactly like this one, Only it was 165.00 and in only 2 years, traded to .25 Cents! So I bought the 50K, and it traded to a low of .09 Cents. So, I bought 550,000 shares more. I shut down the computer, and checked on it Once a month. After 2 solid years, and plenty of ups and downs (So emotional, YES EMOTIONAL!) I went to sleep with $348,000.00 Dollars in my account after it traded up to that over those 24 months. I woke up the next morning with 1,215,000.00 in my account, as the Company got bought out for over 2.00 a share! Have patience, and forget daily action. It means nothing for the future of this Company.
Dcth has yet to see a horrible day, consistent gains couldn't be anymore happy bullish
I do not believe the new entry on fda is for patent... it talks about export ready product... which is different than merely a patent. are we looking at tripple whammy from dcth soon like patent approval + product fda approval + BO or merger. certainly looks interesting
The bigwigs should give the shareholders some kind of news. These people just don't care, so why even bother to invest in their company.